Clinical trial · Observational
MMRF CureCloud Research Initiative
The MMRF CureCloud Multiple Myeloma Research Initiative
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared to a bone marrow aspirate. We decided that our resources are best served in other areas at this time.
Summary
Brief summary (as posted)
The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing collection of their electronic medical records information.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| liquid biopsy | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CureCloud Direct to Patient
- interventionNames
- Genetic: liquid biopsy
Primary outcomes (1)
- measure
- Collection and Analyses of Clinical Information and Peripheral Blood Samples
- timeFrame
- 5 years
- description
- Patients that have been diagnosed with active Multiple Myeloma will be asked to share their clinical information and blood samples to help scientists and researchers understand these conditions better. The study will use submitted blood samples to perform comprehensive research that will include, among others, genomic and immune characterization, as well as collect past and present medical records to combine and compare with the blood sample analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with active Multiple Myeloma 2. Patients have signed an online consent form Exclusion Criteria: 1. Patients who live outside the United States 2. Patients with a diagnosis other than Multiple Myeloma or a known or suspected precursor to Multiple Myeloma
References
Publications (0)
Data not yet available